TITLE

OTHER NEWS TO NOTE

PUB. DATE
June 2010
SOURCE
BioWorld Today;6/7/2010, Vol. 21 Issue 108, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs concerning the biotechnology industries, which include the licensing agreement between Ascalon International Inc. and CerRx Inc., the agreement between Emisphere Technologies Inc. and Novartis AG and preclinical data on the dual agonist of Toll-like Receptor 7 (TLR7) and TLR8 from Idera Pharmaceuticals Inc.
ACCESSION #
51310351

 

Related Articles

  • Santhera In-Licenses Novartis Drug For Muscular Dystrophy. Sheridan, Cormac // BioWorld International;7/4/2007, Vol. 12 Issue 27, p1 

    The article reports that Santhera Pharmaceuticals AG has closed a licensing deal with Novartis AG for the use of omigapil (SNT-317). SNT-317 is a compound that has a potential to treat predominant forms of congenital muscular dystrophy. Santhera would gain access to preclinical and clinical data...

  • Other News To Note.  // BioWorld Today;8/9/2010, Vol. 21 Issue 152, p2 

    This section offers news briefs on the biotechnology industry. The board of Cypress Bioscience Inc. has rejected a proposal by shareholder Ramius LLC to acquire all of its outstanding shares for four U.S. dollars each in cash. A new supply agreement was signed by GenVec Inc. with Novartis AG to...

  • Oncology market: Cytotoxics face biotech challenge.  // PharmaWatch: Cancer;April 2003, Vol. 2 Issue 4, p22 

    Reports that the oncology market has been dominated by cytotoxic treatments. Sales performance of Gleevec from Novartis AG; Recommendation of Bexxar from Corixa Corp. and GlaxoSmithKline PLC for approval by the U.S. Food and Drug Administration; Need of biotechnology companies for licensing...

  • Biotech seeds may bear fruit after European visit. Webb // San Diego Business Journal;11/08/99, Vol. 20 Issue 45, p8 

    Reports on Switzerland-based pharmaceutical firm Novartis AG's planned biotechnology investments in San Diego, California, as of November 8, 1999. City-based biotechnology industry executives' attendance in industry conferences in London, England.

  • Tech startup of the month. Peterson, Eric // ColoradoBiz;May2002, Vol. 29 Issue 5, p49 

    Features the GlobeImmune Inc. in Denver, Colorado. Production of vaccine from brewer's yeast proteins; Focus on the HIV disease; Licensing agreement with Novartis.

  • Novartis in AMD deal.  // Optometry Today;5/23/2014, Vol. 54 Issue 10, p5 

    The article reports on a licensing agreement between pharmaceutical companies Novartis and Ophthotech concerning the non-U.S. commercial rights to Novartis' wet age-related macular degeneration (AMD) drug Fovista.

  • Agricultural biotechnology. Fairley, Peter // Chemical Week;7/22/1998, Vol. 160 Issue 27, p16 

    Reports on the expansion of the 1993 cross-licensing agreement between Novartis and Dow subsidiary Mycogen. Coverage of the licensing agreement; Products to be marketed by the companies; Comments from Michael Muston, president of Mycogen's seeds unit.

  • Debiopharm signs licensing agreement with Novartis.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p16 

    The article reports that Swiss biopharmaceutical firm Debiopharm Group has signed a licensing agreement with Novartis AG for the commercialization, manufacture and development of Debio 025, a selective, cyclophilin inhibitor with a potent antihepatitis C virus (HCV) effect.

  • Novartis Acquires Hepatitis C Franchise.  // Chemical Market Reporter;3/31/2003, Vol. 263 Issue 13, p2 

    Focuses on the stakes acquired by Novartis AG from biotechnology company Indenix in Cambridge, Massachusetts. Terms of the deal; Payments made for the licensing of hepatitis drugs.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics